Positive Long-Term Outlook for Xenon Pharmaceuticals Amid Anticipated Epilepsy Data Event

Leerink Partners analyst Marc Goodman has maintained their bullish stance on XENE stock, giving a Buy rating on January 23.

Marc Goodman’s rating is based on a blend of factors that contribute to a positive outlook for Xenon Pharmaceuticals. One of the key reasons is the anticipation of a significant data event in the second half of 2025 related to epilepsy treatment, which is expected to be a major catalyst for the company’s stock. Despite some investor concerns about an upcoming data disclosure from an investigator-led study on major depressive disorder, Goodman notes that the study is small and not designed to prove efficacy, thus any stock reaction to this data might be minimal.
Goodman’s confidence is further bolstered by the expectation that Xenon’s stock will appreciate as investors prepare for the positive epilepsy data event. He projects that the stock could reach the $45-50 range as this event approaches. The potential for positive safety data, similar to previous studies with lower adverse effects, also supports his optimistic view. Overall, despite potential short-term uncertainties, Goodman sees a strong long-term growth prospect for Xenon, justifying the Buy rating.

In another report released on January 23, Wedbush also maintained a Buy rating on the stock with a $43.00 price target.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XENE in relation to earlier this year.